Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 1, 2002Pharmacogenetics

Identification and functional characterization of new potentially defective alleles of human CYP2C19

View Full Paper
Ask AI
Bookmark
Share

Authors

JBJoyce BlaisdellQingdao UniversityHMHarvey W. MohrenweiserUniversity of North Carolina at Chapel HillJJJonathan JacksonBelfast Health and Social Care Trust

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Blaisdell et al. (2002) studied this question.

synapsesocial.com/papers/6a8a74c2f8670bac6e337826https://doi.org/10.1097/00008571-200212000-00004
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Genetic polymorphism of S-mephenytoin 4??-hydroxylation in African-Americans1996 · 45 citations
  2. 2Amitriptyline Pharmacokinetics and Clinical Response: II. Metabolic Polymorphism Assessed by Hydroxylation of Debrisoquine and Mephenytoin1986 · 61 citations
  3. 3A DNA Polymorphism Discovery Resource for Research on Human Genetic Variation: Table 1.1998 · 834 citations
  4. 4The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase1997 · 267 citations
  5. 5A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype1995 · 94 citations